The diabetes and weight loss drug Ozempic could lower the risk of Alzheimer’s disease among people with type 2 diabetes, ...

Semaglutide, found in Novo Nordisk's Ozempic, may reduce Alzheimer's risk in type 2 diabetes patients, per new research. FDA ...

Semaglutide, the active ingredient found in Ozempic and Wegovy, may reduce the risk of Alzheimer’s disease, a new study published Thursday morning finds.

A new study is adding to evidence that GLP-1 drugs such as Novo Nordisk's semaglutide and Eli Lilly's tirzepatide could also ...

As obesity rates in the United States soar, insurance companies, including Medicaid and Medicare, are facing financial headwinds to pay for prescription drugs for weight loss. Semaglutide, the generic ...

Quebec's health insurance board currently doesn't cover Ozempic and similar weight-loss medication unless they are prescribed for patients who are diagnosed with diabetes.

Novo Nordisk has asked the FDA to add semaglutide to a list that would effectively block manufacturing of copycat versions of ...

Advocates for diabetes patients who need insulin to survive worry the nation's supply is unreliable. Meanwhile, use of ...

Novo Nordisk’s blockbuster drug Ozempic (NVO) is linked to yet another health benefit. This time it’s lowering the risk of ...

Drugs like Wegovy may trim your waistline but not medical costs, according to an analysis of U.S. health insurance claims ...

Novo Nordisk (NVO) has asked the FDA to ban cheap copies of its weight loss drugs Wegovy and Ozempic, arguing they pose safety risks, ...

Researchers have linked Novo Nordisk’s semaglutide to a 40% to 70% reduction in the risk of Alzheimer’s disease diagnosis in ...